312 related articles for article (PubMed ID: 25391374)
1. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
[TBL] [Abstract][Full Text] [Related]
2. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
3. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
5. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
Gayle SS; Castellino RC; Buss MC; Nahta R
Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
Christodoulou C; Oikonomopoulos G; Koliou GA; Kostopoulos I; Kotoula V; Bobos M; Pentheroudakis G; Lazaridis G; Skondra M; Chrisafi S; Koutras A; Bafaloukos D; Razis E; Papadopoulou K; Papakostas P; Kalofonos HP; Pectasides D; Skarlos P; Kalogeras KT; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(6):461-471. PubMed ID: 30343280
[TBL] [Abstract][Full Text] [Related]
8. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
9. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
14. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
[TBL] [Abstract][Full Text] [Related]
16. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
[TBL] [Abstract][Full Text] [Related]
17. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
19. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
[No Abstract] [Full Text] [Related]
20. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Wang SE; Xiang B; Zent R; Quaranta V; Pozzi A; Arteaga CL
Cancer Res; 2009 Jan; 69(2):475-82. PubMed ID: 19147560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]